Ventas VTR
Real Estate · REIT - Healthcare Facilities · Synthos Deep Dive · 2026-07-03
The Overview
Ventas is a landlord, not an operator. It owns roughly 1,400 properties — mostly senior-housing communities (assisted living, memory care), plus medical-office and research buildings — and it makes money the way a landlord does: rent and the profits from running those senior homes. The big idea is simple demographics: the 70 million Baby Boomers are starting to turn 80 in 2026, and 80-somethings are exactly who move into senior housing. More demand, more full buildings, more rent.
The business is doing well — the senior-housing portfolio's profit grew 15%+ last quarter and buildings are filling up. The problem is the price. The stock has already jumped about 47% in the past year and now trades right at its highest point in a year, which usually means a lot of the good news is already baked in. You're paying a premium for growth that, while steady, is not fast.
Our verdict is Watch — a fine company we would rather buy on a dip than chase at the top.
Here's what our three scores mean in everyday terms:
- Downside Risk 6/10 (a bit elevated). The demand is recession-resistant and the stock is not jumpy, but the company carries a lot of debt (common for REITs) and the shares are pricey right now, so a stumble would hurt.
- Growth Quality 5/10 (solid, middle-of-the-road). Good, dependable growth for a REIT — roughly 9% a year in the cash-flow measure that matters — but not the kind of fast growth you'd find in tech.
- Exponential Potential 3/10 (low). This is a slow-and-steady demographic story. It should grind higher for years, but it is not going to double quickly.
The one big worry: you are paying a full price at the peak. If interest rates rise or the senior-housing boom cools even a little, the stock could give back a chunk of its gains.
Putting a number on it: our fair-value estimate is $89 against a current price of $91.80 — a premium price for a business we still like.
Our summary metrics
Low beta (0.73) & non-cyclical demand, but 5.0× net-debt/EBITDA and 24× P/FFO at a 52-wk high with RSI 76.
~9% FFO/share and 15%+ SHOP NOI growth off the Boomer wave — good for a REIT, not secular-growth-fast.
Demographic tailwind is real but slow; a $45B levered REIT with high-single-digit FFO growth cannot multibag.
What does “fair value” mean?
Fair value is Synthos’s estimate of what one share is worth today, based on our model of the company’s future cash generation and the risks to it. It is not a price target or a prediction of where the stock trades next quarter — it’s the price where we think risk and reward are balanced. Above it, you’re paying for outcomes better than our base case; below it, the market is offering a margin of safety.
The model’s inputs and weightings are proprietary — they’re the product. What we publish is the output, plus an independent, public-math cross-check further down the page (“Check our number”) so you can judge it for yourself.
What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Exponential Potential
Demographic tailwind is real but slow; a $45B levered REIT with high-single-digit FFO growth cannot multibag.
What could take this further than the base case — and where the market may be underpricing it. Full forward-growth and acceleration math in Deeper analysis, §4 below.
Deeper analysis
Technicals, fundamentals, valuation, and the full expert-claim evidence panel — the detail behind the numbers above.
Reference table
| Street consensus | $95.86 (high $110 / low $88; 19 Buy · 11 Hold · 2 Sell) — context, not our anchor |
| Valuation | ~24× 2026E FFO/share ($3.86) · EV/EBITDA 23.5× · P/S 7.3× · GAAP EPS is not the right lens for a REIT (§6) |
| Technicals | Uptrend but stretched — $92.57 at the 52-wk high, RSI 76 (overbought), +47% 12-mo (SPY +21%) |
| Conviction | Low — zero expert claims in the Synthos KB; the call rests on fundamentals + quant only |
| Position sizing | If owned, income/defensive sleeve, ~1–3%; prefer to wait for a pullback |
What the experts actually said
No independent expert claims in the Synthos knowledge base yet for VTR — this dive is fundamentals- and technicals-driven, not panel-driven.
Price & moving averages 12 months · 50 & 200-day averages · 52-week range
Solid line = price · dashed line = 50-day average · dotted line = 200-day average · the two thin horizontal lines mark the 52-week high and low. Price above both averages is an uptrend.
Data summary: last close $91.81, 0% below the 50-day average ($92), 8% above the 200-day average ($85) — a mixed trend. 9% below the 52-week high of $101, 37% above the 52-week low of $67.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Data summary: price $91.81 is currently inside the band (band $89–$95).
RSI (14) momentum gauge · 0–100
Above 70 (overbought zone, shaded) = overbought, below 30 (oversold zone, shaded) = oversold. Currently 48.
MACD 12 / 26 / 9 · trend & momentum
The MACD line crossing above the signal line (bars flip to the up color) = momentum turning up; crossing below (bars flip to the down color) = turning down. Bar height = the size of that gap.
Data summary: MACD is currently above its signal line by 0.07, positive momentum.
Relative performance vs S&P 500 & its sector (XLRE (sector)), set to 100 a year ago
Solid = VTR · dashed = S&P 500 · dotted = XLRE (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Forward revenue & earnings actual → estimate · "FY" = fiscal year, "E" = estimate
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
1. What it is
Ventas, Inc. (NYSE: VTR) is an S&P 500 healthcare Real Estate Investment Trust (REIT) headquartered in Chicago, with more than 1,400 properties across the United States, Canada, and the United Kingdom. Founded in the 1990s and led by long-tenured Chairman/CEO Debra A. Cafaro, Ventas sits "at the nexus of healthcare and real estate," monetizing the aging-population trend. Fiscal year ends December 31.
Revenue mix (FY2025, from segment filings):
- By segment: Senior Living Operations (SHOP) $4.28B (73%) · Outpatient Medical & Research Portfolio $0.90B (15%) · Triple-Net Leased Properties $0.60B (10%). The story is overwhelmingly a senior-housing operating (SHOP) story — Ventas takes the operating upside (and downside) of running the buildings, not just collecting fixed rent.
- By geography: United States $5.21B (89%) · Canada $0.55B (9%) · United Kingdom $0.07B (1%). US-concentrated, so US senior-housing demand and US interest rates dominate.
Critical framing for a REIT. GAAP net income and EPS badly understate a REIT because depreciation on real estate is a huge non-cash charge. FY25 GAAP EPS was just $0.55, but management's Normalized FFO (funds from operations, the REIT cash-earnings standard) runs at a ~$3.86/share (2026E) pace. Every valuation judgment below uses FFO, not GAAP EPS. (The FMP "EPS" estimates — $0.62 for 2026 — are GAAP and should be ignored for valuation.)
2. The expert thesis — why the panel is bullish (traceable)
There is no expert coverage of Ventas in the Synthos knowledge base. total_claims = 0, net_bullish_voices = 0, and the top list is empty. No independent voice in our panel has staked a traceable, skill-weighted claim on VTR.
We will not manufacture conviction we do not have. Accordingly, this verdict is fundamentals- and quant-driven only, built from the FMP financials, analyst estimates, management's own SEC-filed guidance (§9, half-weighted), and the technical/valuation picture. Where a conviction name like LLY earns a "Buy — Core" partly on 13 reconciled expert voices, VTR gets no such lift — and that absence is itself a reason the verdict lands at Watch rather than a conviction Buy.
The nearest thing to a "street" read is the sell-side: 19 Buy / 11 Hold / 2 Sell, consensus rating "Buy," price-target consensus $95.86 (high $110, low $88). We treat that as context in §6, not as a Synthos conviction input.
3. Synthos scores & the Bull / Base / Bear cases
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
| Score | 0–10 | The read |
|---|---|---|
| Downside Risk (lower = safer) | 6 · Elevated-moderate | Low beta (0.73), non-cyclical demand and a 52-wk max drawdown of ~0% cut both ways — but net-debt/EBITDA 5.0× (mgmt) / 5.1× (FMP), ~24× FFO, and the stock at its high on RSI 76 leave little cushion. |
| Growth Quality | 5 · Solid | ~9% Normalized FFO/share growth and 15%+ SHOP same-store NOI off the Boomer wave, occupancy +310bps — genuinely good for a REIT, but ROIC is thin (ROIC ~3%, ROE ~2%) and it is not secular-growth-fast. |
| Exponential Potential | 3 · Low | A demographic grinder: high-single-digit FFO growth, heavy leverage, $45B cap. Real multi-year tailwind, but structurally cannot multibag. |
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is by definition the expected path, so a weighted blend would just restate it with false precision. Instead the cases bound the range, and the scores above summarize them. All targets anchor on P/FFO, the correct REIT lens.
| Case | Key assumptions | Fair value |
|---|---|---|
| Bull | Boomer wave + $3B/yr senior-housing investment drives SHOP NOI +15%; 2027E FFO/share ~$4.25; rates stay benign; market pays a premium ~24.5× FFO. | ~$105 (+13%) |
| Base (our anchor) | Guidance roughly holds — 2026E Normalized FFO/share $3.86, growing to ~$4.15 (2027E) at ~8%; multiple normalizes to a still-full ~21.5× FFO. | ~$89 (−4%) |
| Bear | Rates rise / SHOP momentum cools; FFO/share growth slows to mid-single digits (~$4.00); multiple de-rates to a sector-typical ~17.5× FFO. | ~$70 (−24%) |
Synthos fair value = the base case, ~$89 (−4%), with the full $70–$105 span as the honest range. Our base sits below the Street's $95.86 consensus because we are unwilling to underwrite ~24× FFO at a 52-week high; our bull roughly matches the Street's $110 high. This is a tracked call — the Forecaster Scorecard grades it once it matures.
4. Exponential Potential
Synthos separates compounders (durable, steady returns) from exponentials (accelerating multi-baggers-from-here). VTR is a modest demographic compounder, not an exponential:
- Forward growth: Street revenue CAGR FY25→FY29E ~10.4% ($5.83B → $8.68B); the metric that matters, Normalized FFO/share, grows ~9% (management, 2026). Steady, not steep.
- Acceleration (2nd derivative): modestly positive right now — SHOP same-store NOI +15% and occupancy +310bps are the best prints in years as the Boomer wave inflects, and management raised 2026 FFO guidance. But this is a demographic ramp measured in years, not a demand shock; the ceiling on FFO/share growth is high-single/low-double digits.
- Room to run: the senior-housing TAM is large and the 80+ population genuinely swells for a decade, so demand runway exists. But at a $45B cap with 5.0× net-debt/EBITDA, a REIT that grows FFO ~9% and pays most of it out as dividend cannot compound into a multibagger — leverage and the payout cap the reinvestment engine.
- Reinvestment: $3B of 2026 senior-housing investment (raised from $2.5B), largely equity-funded ($2.4B of equity raised, including forward sales) — accretive, but the equity issuance dilutes per-share upside.
Exponential Potential: Low (3/10). Own VTR, if at all, for durable high-single-digit FFO growth plus a ~2.2% dividend riding a real demographic wave — never for a fast multibagger. That honest framing puts it in an income/defensive sleeve, not a growth or degen sleeve.
5. Financials (real numbers — FMP annual/quarterly; FFO from mgmt release)
- Revenue: FY25 $5.83B, +18.5% (FY24 $4.92B, +9.5% on FY23 $4.50B). Growth is accelerating as SHOP scales and acquisitions close.
- Quarterly trajectory: Q1'25 $1.36B → Q2 $1.42B → Q3 $1.49B → Q4 $1.57B → Q1'26 $1.66B (+22% YoY). Consistent sequential build.
- FFO (the REIT earnings metric): Q1'26 Normalized FFO/share $0.94, +9% YoY; full-year 2026 guidance $3.82–$3.89 (midpoint $3.86), raised from $3.78–$3.88. Total-company NOI +14%, same-store cash NOI +9%, SHOP same-store cash NOI +15%+.
- Margins & returns: EBITDA margin ~40% TTM, but ROIC ~3.1%, ROE ~2.1%, ROA ~0.9% — thin, because a levered REIT earns a spread over a large asset base. GAAP net margin 4.2%.
- GAAP earnings (understated by design): FY25 net income $251M, EPS $0.55 — depreciation ($1.28B) is the wedge between GAAP and FFO. Do not value a REIT on this.
- Cash flow: operating CF $1.68B FY25, capex −$0.36B, FCF ~$1.32B; dividends paid $860M — dividend is covered by FFO/AFFO, not by GAAP EPS.
- Balance sheet: total debt $13.2B, net debt $12.5B, net-debt/EBITDA 5.0× (mgmt, Q1'26) — the tenth consecutive quarter of sequential improvement, down from higher levels. $5.5B liquidity. Current ratio 0.15 is normal for a REIT (no inventory, long-dated debt). Leverage is the defining risk metric here.
6. Valuation — priced in or room?
Use FFO, not GAAP EPS. The FMP P/E of 165× and the FMP "EPS" estimates are GAAP artifacts and meaningless for a REIT. On the right metric:
- P/FFO: $92.57 / $3.86 (2026E) = ~24.0×. For a healthcare REIT growing FFO ~9%, that is a full-to-rich multiple — the highest-quality healthcare REITs have historically traded ~15–20× FFO, and 24× embeds continued SHOP momentum.
- EV/EBITDA 23.5× · EV/Sales 9.4× · P/S 7.3× — all elevated versus REIT norms, reflecting the growth premium the market now assigns to the senior-housing recovery.
- Dividend yield ~2.2% ($2.00/share) — modest for a REIT, and the payout is being partly redirected into growth investment.
- FMP letter rating C+ (overall score 2/5), dinged specifically on price-to-earnings (1/5) and price-to-book (1/5) — i.e., the quant screen flags valuation, consistent with our read.
Street targets (context): consensus $95.86, high $110, low $88. Our base FV ~$89 sits below consensus because we will not anchor to ~24× FFO at a 52-week high on an overbought tape; the Street is essentially assuming the current multiple holds. Not a value entry — a quality-REIT-at-a-full-price, where the entry price is the whole argument for waiting.
7. Technicals (from the tech block)
- Trend: up, but extended. $92.52 sits above the 50-DMA ($85.78) and 200-DMA ($80.19), 50 above 200 (golden-cross posture), MACD +1.48 (positive).
- Location: exactly at the 52-week high ($92.52) —
pct_from_hi = 0.0— and +47% off the 52-week low ($62.76). Max drawdown from peak ~0%: this is a name making new highs with no recent shakeout. - Momentum: RSI(14) 76 — overbought (>70). This is the clearest single caution flag: buying at a fresh high on an overbought RSI is a poor risk-entry.
- Relative strength: VTR +47.2% 12-mo vs SPY +20.6%, and +12.8% 3-mo vs SPY +13.7% (roughly in line lately) and vs QQQ +22.0% 3-mo (lagging tech). Strong 12-month leadership, but the momentum edge has narrowed recently.
- Read: technicals say the trend is healthy but the entry is stretched. A pullback toward the rising 50-DMA (~$86) would be a materially better-risk add. No technical urgency to buy at $92 into RSI 76.
8. Moat & competitive position
A REIT's "moat" is portfolio quality, cost of capital, operating platform, and scale — not patents. Ventas's edges: (1) scale — 1,400+ properties and ~900 senior-housing communities give it operating data and operator relationships smaller peers lack; (2) its proprietary Ventas OI™ operating-intelligence platform, which management credits for occupancy/RevPOR outperformance; (3) a "Right Market, Right Asset, Right Operator" capital-allocation discipline; and (4) an improving balance sheet (10 straight quarters of deleveraging) that lowers cost of capital versus weaker peers. The tailwind — the 80+ population inflecting for a decade — is shared by the whole senior-housing subsector, so it is an industry tailwind more than a company moat.
Peer set (FMP-supplied REITs, market cap): the FMP peer list is generic real-estate, not clean comps — AvalonBay $27.5B (apartments), Equity Residential $26.2B (apartments), Extra Space $31.5B (storage), Crown Castle $33.4B / SBA $19.6B (towers), Iron Mountain $34.9B (records), VICI $29.1B (gaming), CoStar $12.3B (data). The relevant healthcare-REIT comps are Healthpeak (DOC, $15.1B) and Omega Healthcare (OHI, $14.7B), both in the list, plus Welltower (not listed) as the closest senior-housing peer. Against DOC/OHI, VTR carries the richer growth-driven multiple; the question is whether SHOP momentum justifies the premium.
9. Management, capital allocation & guidance
- Leadership: Debra A. Cafaro has been Chairman/CEO for over two decades — deep, tested through prior cycles (the description touts "over two decades" of navigating market fluctuations). Long-tenured, credible senior-housing operator.
- Capital allocation: raised 2026 senior-housing investment volume to $3B (from $2.5B), funded largely with equity ($2.4B raised incl. forward sales, 10.6M shares settled for ~$0.8B). Accretive investment is good; heavy equity issuance is per-share dilutive and is the price of deleveraging while growing. Net-debt/EBITDA improved to 5.0×, tenth consecutive quarter of improvement. Dividend $2.00/share (~2.2% yield), payout being balanced against growth investment.
- Insider activity: the July 1 filings are routine director stock awards at $89.65 (compensation, not open-market conviction). One genuine positive: director Michael Embler bought 2,500 shares on the open market at $78.81 on 2026-06-03 (P-Purchase) — a real, if small, insider vote of confidence below current price. No alarming discretionary selling in the sampled window.
- Management's own guidance (half-weighted — their own book): from the 2026-04-27 SEC 8-K (Item 2.02) Q1'26 earnings release, management raised full-year 2026 guidance: Normalized FFO/share $3.82–$3.89 (midpoint $3.86), Nareit FFO/share $3.69–$3.76, Attributable Net Income/share $0.56–$0.63. Cafaro: "As the nearly 70 million Baby Boomers begin turning 80 in 2026, we expect durable demand… We are increasing our full year guidance." This is management's self-interested framing (half-weight), but it is a raise backed by real SHOP prints (+15% same-store NOI, +310bps occupancy) — credible.
10. Catalysts & what to watch
- Next earnings: 2026-07-29 (Q2'26; Street EPS $0.14 GAAP, revenue ~$1.68B). The lines that matter: SHOP same-store NOI growth, occupancy trend, and any further FFO-guidance raise.
- SHOP occupancy & RevPOR: the direct read on the Boomer-demand thesis; continued +300bps occupancy = thesis intact.
- Interest rates: as a levered REIT, VTR's multiple and cost of capital are rate-sensitive; management already flagged "higher interest rates" as a partial offset to guidance.
- Investment pace & funding mix: hitting $3B of accretive senior-housing investment without excessive dilution.
- Deleveraging: an eleventh consecutive quarter of net-debt/EBITDA improvement below 5.0× would further de-risk the balance sheet.
Thesis tripwires (what would change the call): SHOP same-store NOI decelerating below high-single digits; occupancy gains stalling; a guidance cut; net-debt/EBITDA reversing higher; or a rate spike compressing the FFO multiple. On the upside, a pullback toward the 50-DMA (~$86) with SHOP momentum intact would upgrade this from Watch toward Buy — Tactical.
11. Key risks
- Valuation / de-rating (primary): ~24× FFO at a 52-week high on RSI 76 leaves little margin; a multiple normalization to ~18× alone is a ~−25% move even with flat FFO.
- Leverage & rates: net-debt/EBITDA 5.0× means rising rates raise refinancing cost and compress the REIT multiple simultaneously — a double hit.
- SHOP operating risk: unlike triple-net rent, Ventas bears senior-housing operating costs (labor, insurance); margin can compress if wage inflation outruns RevPOR.
- Dilution: growth is being funded with equity; aggressive issuance caps per-share FFO growth.
- No expert corroboration: zero Synthos KB coverage means no independent conviction cross-check — the thesis rests entirely on fundamentals, quant, and management's own (self-interested) guidance.
12. Verdict, position sizing & monitoring
Watch. Ventas is a genuinely well-run healthcare REIT with a real, multi-year demographic tailwind — SHOP same-store NOI +15%, occupancy +310bps, FFO/share +9% and guidance raised, a long-tenured CEO, and a balance sheet deleveraging for ten straight quarters. Those are the ingredients of a quality income compounder. But the price does not cooperate: ~24× FFO at a fresh 52-week high on an overbought RSI (76), for high-single-digit FFO growth, with a base-case fair value (~$89) slightly below today's $92.57 and below the Street's $95.86. There is no expert coverage in the Synthos KB to lift the conviction. The right move is to wait for a better entry, not to chase the top.
- Sizing: if owned for income/defense, ~1–3%; new capital is better deployed on a pullback toward the ~$86 50-DMA. This is not a conviction core position.
- Monitoring: re-underwrite on the §10 tripwires; a pullback into the mid-$80s with SHOP momentum intact would upgrade toward Buy — Tactical. This verdict is logged as a tracked Synthos call as of 2026-07-03 at $92.57.
- Single biggest risk: paying a full ~24× FFO multiple at the high — a de-rating from rates or cooling SHOP momentum is the most likely way to lose money here.
Provenance & disclosures
- Traceability: 0 KB claims, breadth 0 — Ventas has no expert coverage in the Synthos knowledge base. This verdict is explicitly fundamentals- and quant-driven; no conviction was fabricated (claim-ID reconciliation is not applicable because there are no claims to cite).
- Data as-of: fundamentals 2026-03-31 (Q1'26) · estimates & prices 2026-07-02/03 · management guidance from the 2026-04-27 SEC 8-K (Item 2.02). Forward figures are analyst consensus (FMP) or management guidance, labeled as estimates.
- REIT caveat: GAAP EPS and FMP P/E are not meaningful for a REIT; all valuation uses management's Normalized FFO. FMP "EPS" estimates are GAAP.
- Management caveat: Ventas's raised 2026 guidance is management's own book, half-weighted by design.
- Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
- Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").